A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
Trial details
- Registry ID
- NCT06872125
- Drugs studied
- Sham Comparator, zorevunersen
TrialRedline tracks 2 clinical trials sponsored by Stoke Therapeutics, Inc: 1 Phase 3, 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromeNCT06872125 | Sham Comparator, zorevunersen | Active not recruiting | 2027-03Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| An Open-Label Extension Study of STK-001 for Patients With Dravet SyndromeNCT04740476 | zorevunersen (STK-001) | Active not recruiting | 2029-03-31Estimated |
Names as written in the registry records.
NCT06872125 · Stoke Therapeutics, Inc
Before: Recruiting. After: Active not recruiting.
NCT06872125 · Stoke Therapeutics, Inc
Before: 150 participants (planned). After: 170 participants (planned).
NCT04740476 · Stoke Therapeutics, Inc
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Safety of multiple doses of STK-001. After: Measure: Safety of multiple doses of zorevunersen.